Composition for preventing or treating keloid or hypertrophic scars
AssigneeIndustry-University Cooperation Foundation Hanyang University
InventorsChae Ok Yun, Won Jai Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating a keloid disease or scars. The inventors of the present invention discovered that mortalin expression inhibition and the interaction between mortalin and p53 may be new targets for keloid treatment. In the present invention, apoptosis and an anti-fibrotic effect were verified by preparing a mortalin-specific shRNA (dE1-RGD/GFP/shMOT) and injecting same in a keloid spheroid. Thus, by reducing ECM expression and inducing apoptosis in a keloid spheroid, mortalin knockdown may be very usefully employed for keloid treatment.
Claims8
A method of treating keloid diseases or scars, comprising:
- administering a therapeutically effective amount of an inhibitor, which suppresses an expression of a mortalin gene or an activity of a mortalin protein, to a subject in need thereof,
- wherein the inhibitor is shRNA, siRNA, miRNA, an antisense oligonucleotide, a ribozyme, a DNAzyme, a peptide nucleic acid, an antibody or an aptamer, and
- wherein shRNA, siRNA, miRNA, the antisense oligonucleotide, the ribozyme, the DNAzyme or the peptide nucleic acid comprises a sequence complementary to mRNA or DNA of the mortalin gene and suppresses an expression of the mortalin gene, and the antibody or the aptamer specifically binds to the mortalin protein and suppresses the activity of the mortalin protein.
A method of treating keloid diseases or scars, comprising:
- administering, to a subject in need thereof, a pharmaceutical composition, which comprises:
- (a) a therapeutically effective amount of an adenovirus expressing an oligonucleotide for inhibiting an expression of a mortalin gene as an active ingredient;
- and
- (b) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.